pKLV2-U6gRNA5(gGFP)-PGKmCherry2AGFP-W Citations (3)
Originally described in: A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJ, Iorio F, Pina C, Vassiliou GS, Yusa K Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079. PubMed Journal
Articles Citing pKLV2-U6gRNA5(gGFP)-PGKmCherry2AGFP-W
| Articles |
|---|
Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway.
Chai AWY, Yee PS, Price S, Yee SM, Lee HM, Tiong VK, Goncalves E, Behan FM, Bateson J, Gilbert J, Tan AC, McDermott U, Garnett MJ, Cheong SC.
Elife. 2020 Sep 29;9. pii: 57761. doi: 10.7554/eLife.57761.
PubMed
Associated Plasmids |
| CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia. Stewart ML, Gibbs J, Watanabe-Smith K, Nguyen A, Kenna I, Thiel-Klare K, Kaempf A, Bottomly D, Kurtz SE, Eide CA, Long N, Saultz JN, Sax L, Huang A, McWeeney SK, Chang BH, Tyner JW. Cell Rep Med. 2026 Jan 20;7(1):102526. doi: 10.1016/j.xcrm.2025.102526. Epub 2025 Dec 29. PubMed |
| CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. Watterson A, Picco G, Veninga V, Samarakoon Y, Cattaneo CM, Vieira SF, Karakoc E, Bhosle S, Battaglia TW, Consonni S, Halim TYF, Voest EE, Garnett MJ, Coelho MA. Cell Rep Med. 2026 Jan 20;7(1):102565. doi: 10.1016/j.xcrm.2025.102565. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.